Anti-Granulocyte–Macrophage Colony–Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Respiratory and Critical Care Medicine"
DOI: 10.1164/rccm.202108-1859oc
Abstract: Rationale GM-CSF (granulocyte–macrophage colony–stimulating factor) has emerged as a promising target against the hyperactive host immune response associated with coronavirus disease (COVID-19). Objectives We sought to investigate the efficacy and safety of gimsilumab, an anti–GM-CSF… read more here.
Keywords: gimsilumab; granulocyte macrophage; trial; placebo ... See more keywords